National Cancer Centre Singapore – NCCS shared a post on LinkedIn about a recent article by M.M. Zheng et al. published in ESMO Annals of Oncology:
“Good news is on the horizon for lung cancer patients!
A recent study co-authored by Dr Aaron Tan from NCCS showed that new lung cancer treatments, such as Immune Checkpoint Inhibitor (ICI) and Tyrosine Kinase Inhibitor (TKI) therapies, improve survival even after cancer has spread to the lining of the brain and spinal cord. Results demonstrate the crucial role that research and innovation play in cancer therapeutics, and its potential to impact clinical outcomes and improve overall survival for patients.”
Title: The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study
Authors: M.M. Zheng, Y. Xia, K. Pan, F. Sun, A.C. Tan, X.R. Dong, H.Y. Tu, L.B. Tang, Y.S. Li, K. Yin, M. Borgeaud, S. Singhal, E. Zhu, J. Zhang, M. Nilsson, J. Wu, D.L. Gibbons, H. Wakelee, J.W. Neal, J. Lee, A.A. Vaporciyan, W. Ringsurongkawong, H.T. Tran, R.Z. Zhang, T. Zhang, Q. Zhou, W.Z. Zhong, W. Li, Y.C. Zhang, J.W. Riess, A. Addeo, J.V. Heymach, N. Myall, D. Tan, Y.L. Wu, X. Le
Read the Full Article on ESMO Annals of Oncology

More posts about National Cancer Centre Singapore.